WilmerHale advised Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, on its underwritten public offering of 21,827,549 shares of common stock at a public offering price of $18.44 per share. This includes 2,847,071 shares issued upon the full exercise by the underwriters of their option to purchase additional shares. The gross proceeds to Dyne from the offering were approximately $402.5 million, before deducting underwriting discounts and commissions and offering expenses payable by Dyne. All shares in the offering were sold by Dyne.

The WilmerHale team was led by Stuart Falber and Scott Lunin, and included Erin Bruynell Gallagher, Sam Wizon, and Abigail King.